PCD Franchise Model of Production

The PCD model in the pharmaceutical industry operates on a monopoly basis, with not more than one vendor in one particular district. The vendor’s have their own medical representatives visiting the doctors. Medicines can be of two types- Ethical Medicines and Generic Medicines, ethical medicines are usually life saving drugs these are regulated strictly by the government other in terms of quality standards and their prices, these cannot be sold at prices other than Government approved ones.

Ethical drugs are also produced as per predetermined quotas. On the other hand, generic drugs are bulk produced hence quality of these are not as high as ethical drugs, prices of these are not administered by Government but determined by the market forces usually these are cheaper than ethical drugs. Logo’s of these drugs may not be very uniform and usually these come in glossy packing to attract consumers.  Big private hospitals usually always use ethical drugs and qualified doctors writing the prescription on their letter pads only prescribe these.

However in India still there are ample doctors who don’t use letter pads for writing prescriptions they would write on blank sheets these would often carry prescriptions of generic drugs, quality of which is not always very high. Law exists against prescribing drugs of low quality; hence the certified doctors using proper letter pads would usually always prescribe ethical drugs so that they are free of any risk.  In our country people want can afford only cheap medicines here people themselves may ask the doctors or chemists to give the cheaper generic drugs than ethical drugs.

There are many companies which besides being involved in PCD (Propaganda cum Distribution) Franchise in India also do manufacturing for the big pharmaceutical companies this arrangement is known as third party production.

Third party production model has really taken off in the last decade this change is due to the Government policy of promoting business through tax rebates where third party producers have blossomed. This model usually lowers input cost as the supply chain is not as long and hence ensures economy for the end user.  So in the near future this market is expected to grow further. Big corporate have understood this and they themselves are into this market. Anybody interested in knowing more about third party and PCD producers can get in touch with the ‘Drug Today’ group. 

Some critics have raised questions regarding the quality standards of drugs produced through third party model. Propaganda cum Distribution is a model of distributorship where big pharmaceutical companies give distributorship rights. PCD products are manufactured by third parties which are quantity oriented and not quality oriented. The major reason being the evolution of high tech manufacturing units in the excise free zone, catering to the needs of the PCD companies.

This has led to blooming of PCD companies which were quite dormant during the period of 1992-2002.The question of ethics and quality is laid to rest as even the biggies are outsourcing many of their requirements from the same manufacturers.

http://www.drugtodayonline.com/

How could harmful FDCs skip NPPA-CDSCO SCRUTINY?

Drug Today Medical Times

Drug Today Medical Times of India

As is reported in a national daily, harmful fixed dose combinations (FDCs) are entering the Indian market unhindered. This would not have been possible without loopholes in the Indian Drug Act. If this was not the case, how could these FDCs skip Central Drugs Standard Control Organization's (CDSCO) scrutiny and National Pharmaceutical Pricing Authority's (NPPA) price control regime?

According to the report, many of the FDCs are available without necessary clinical trials, and with little medical rationale. Both CDSCO and NPPA have miserably failed to in their job. However, rather than taking steps to stem the rot in the industry, National Pharmaceutical Pricing Authority (NPPA) seems obsessed with populism.

The drug regulators are giving jitters to an industry which is already in crisis by imposing undue restrictions on the drug manufacturers and placing essential drugs in the long list of price control. These measures are making the pharma business unviable option for investors.

Drug Today Medical Times is provides The best Drug manufacturers company in India, Pharmacological Index, Pharmacological Research, India's No.1 Health newspaper, latest paramedical and pharmaceutical news, Health and medical AIIMS, A to z medicine in India, Meaning of pharmacological, Pronunciation of pharmacological, Translations of pharmacological, Pharmacological synonyms, pharmacological antonyms, latest medical news, Drug Directory and Pharma Jobs, drug today book and Subscription at http://www.drugtodayonline.com/

Drug Today Medical Times for the Clinical Trial Analytics Industry

Drug Today Medical Times of India Network
The clinical trials services industry is under pressure of twin dimension– cost control and accelerating demand for faster drug development. CEO of Cytel India sees this major challenge as an opportunity for professionals. According to him, his company has launched with a view to bridge the yawning gap in talent availability.

Advances in Genomics, Personalized Medicine, and Risk-based Monitoring will spur increased investment in technology and innovation in services. CEO anticipates that India (and more generally Asia) with its large pool of young, talented human resource, will spearhead the growth of this segment.

The analytics assignments are undertaken by CROs who possess the expertise and capacity to conduct the data analytics work on the data that has been generated during clinical trials.

The pioneering courses offered by the organization square measure Clinical SAS® programming and Clinical SAS® place. The previous aims at providing in depth coaching in SAS® with Associate in nursing orientation to the Clinical Trials Domain. The latter may be a course that provides sensible expertise that closely resembles the assignments entry level SAS® professional’s square measure needed to undertake.
The next course on offer is a strategic response of Cytel to address its growing demand for skilled SAS^® professionals. With a view to meet the requirement of the industry for significant work experience among the pool of aspiring professionals.

The candidates get trained for first six months on various topics which form the building blocks of Clinical Trial Services. The topics range from domain overview and data standards to therapeutic areas and statistics in clinical trials providing an unmatched exposure to the value chain of the industry.

During consequent twelve months they endure rigorous on-the-job coaching that exposes them to assignments that go nighest to the period work they're expected to perform as regular professionals. The candidates rising from this schedule are well-equipped with the theoretical coaching, sensible expertise and sound domain data.

The eligibility criterion is kind of versatile with ability and perspective being the foremost important pre-requisites. The programme is hospitable graduates and post-graduates from a spread of career streams– Life Sciences, Pharmacy, Biotechnology, Statistics, Engineering and applied science.

The latest providing is C-STAR (Clinical SAS® coaching and project-Readiness). This programme bundles the basic building blocks of skilled coaching (SAS® coaching and internship) and augments them by adding what are termed as differentiators among the aspirants – Domain data and Soft-skills. This seven-month programme is good for candidates United Nations agency would like to hitch as junior SAS® programmers within the run Services trade.

SAS and every one different SAS Institute INC. product or service names are registered emblems or emblems of SAS Institute INC. within the USA and different countries. ® indicates USA registration.

Drug Today Medical Times, A complete health based newspaper, A to Z medicine in India, Indian Health and medicine, Medical and pharma jobs, Private Hospital Vacancies, search for current job vacancies in Healthcare hospitals, healthcare management jobs, Physician Jobs, Medical Jobs, Healthcare management jobs and career advice, Nursing Jobs, Drug Today medical Times is the best health and medical advertisement company http://www.drugtodayonline.com/

Tax sops likely on life-saving devices and equipment

Drug Today
The Government appears to be serious to provide big push to the Indian Medical Devices and Equipment Sector. The push is expected to come with the recommendations of a task force constituted by the Government recently to look into difficulties faced in domestic manufacturing of medical devices.

 Pharmaceuticals Secretary has assured that the recommendations would come with two months.
“There are a lot of tariff barriers and it has become very easy to import world class equipment because materials are not available here, any equipment comes here to save a life of a human being we give all tax concessions,” said VK Subburaj, Secretary, Department of Pharmaceuticals.

The Indian Medical Devices and Equipment industry, valued at $5 billion, contributes considerably to India’s $60 billion healthcare sector. Moreover, it is growing at a faster annual rate of 15 per cent than 10-12 per cent growth seen in the healthcare sector in its entirety. A rise in the number of hospitals and the increased requirement for healthcare facilities creates a need for sophisticated devices and equipment, which can provide accurate treatment to individuals.

 However, low penetration, accessibility, affordability, awareness, nascent regulatory environment, low indigenous manufacturing, no distinct status of the industry, complex rules and guidelines and high capital requirement are key challenges, the industry is facing.

 “We have recently formed a task force, we are discussing all issues affecting the growth of this sector, the recommendations will be coming in another two months’ time,” Subburaj, Secretary, said recently at an Assocham Summit. The Task Force that includes stakeholders including Commerce Ministry, DIPP, Health and family welfare Ministry and all associated industries is chaired by the Pharmaceuticals Secretary.

 Senior officials and industry representative feel that ‘Make in India’ policy can provide the much needed push to this sector. The Government is expected to develop a regulatory structure leading to quality products being developed by manufacturers. The last few years have seen an increase in domestic manufacturing of medical equipment. With impetus from the government India is beginning to look forward to being recognized as a manufacturing destination for sophisticated medical technology.
 “We will look at modalities to see that these recommendations are implemented and a conducive atmosphere is created for medical devices manufacturing in India as today it is not conducive that is why the growth is very low,” said  the Secretary.
 “Today we are leaders in pharma sector as we are exporting drugs to 220 countries, it is a proud moment but in medical devices sector we cannot say so as we are almost at the lowest level, our coverage is only about one per cent which has to grow to at least about 10 per cent,” he added.

 The Government urgently needs to rationalise the tax structure if it wants to see India develops in this sector. Currently more than 90 per cent of medical devices and equipment are imported into India and only a small quantity of low profile items are manufactured in the country.

 The Association of Indian Medical Device Industry (AIMED) has suggested inter-ministry co-ordination to deal with complex multiple issues and diverse technologies for enabling indigenous manufacturing of medical devices and equipment in India.
                                                                                                                                                                                                    Drug Drug Today Medical Times of India
                                                                                                                                                                      http://www.drugtodayonline.com/